The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models

Br J Haematol. 2013 Oct;163(1):135-9. doi: 10.1111/bjh.12456. Epub 2013 Jul 9.
No abstract available

Keywords: lymphomas; myeloma; new drug development.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anilides / pharmacology*
  • Anilides / therapeutic use
  • Bone Marrow Cells / drug effects
  • Cell Line, Tumor
  • Drug Evaluation, Preclinical
  • Epigenesis, Genetic / drug effects*
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Hydroxamic Acids / pharmacology*
  • Hydroxamic Acids / therapeutic use
  • Inhibitory Concentration 50
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / genetics*
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / genetics*
  • Stromal Cells / drug effects

Substances

  • Anilides
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • UCL67022